Capricorn Investment Group Acquires HeartFlow Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy HTFL?
Source: Fool
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025 for approximately $48.18 million, reflecting confidence in the company's future prospects.
- Asset Allocation: The new HeartFlow position represents 5.83% of Capricorn's reportable assets under management, highlighting its significance in a portfolio that includes only seven holdings.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, a robust 40% year-over-year increase, yet reported a net loss of $24.4 million, indicating ongoing efforts to manage costs effectively.
- Market Opportunity: With a price-to-sales ratio of 12 near its IPO low, HeartFlow's declining share price suggests a potential buying opportunity for investors looking to capitalize on future growth despite the inherent risks of a newly public company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HTFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.970
Low
35.00
Averages
38.60
High
40.00
Current: 27.970
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Capricorn Investment Group Acquires HeartFlow Shares Worth $48.18 Million
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025, with an estimated transaction value of $48.18 million, indicating confidence in the company's future prospects.
- Asset Impact: This acquisition accounts for 5.83% of Capricorn's 13F reportable assets, although HeartFlow does not rank among the fund's top five holdings, reflecting a selective investment strategy.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, marking a robust 40% year-over-year increase, yet it reported a net loss of $24.4 million, highlighting ongoing efforts to manage costs effectively.
- Market Risks: Despite HeartFlow's price-to-sales ratio nearing a low since its IPO, investors should proceed with caution as the company remains unprofitable and its stock price has declined by 10.7% in 2026.
See More
Capricorn Investment Group Acquires HeartFlow Shares
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025 for approximately $48.18 million, reflecting confidence in the company's future prospects.
- Asset Allocation: The new HeartFlow position represents 5.83% of Capricorn's reportable assets under management, highlighting its significance in a portfolio that includes only seven holdings.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, a robust 40% year-over-year increase, yet reported a net loss of $24.4 million, indicating ongoing efforts to manage costs effectively.
- Market Opportunity: With a price-to-sales ratio of 12 near its IPO low, HeartFlow's declining share price suggests a potential buying opportunity for investors looking to capitalize on future growth despite the inherent risks of a newly public company.
See More
HeartFlow Reports 40% Revenue Growth in Q4 2025
- Significant Revenue Growth: HeartFlow reported total revenue of $49.1 million for Q4 2025, marking a 40% year-over-year increase, with US revenue reaching $44.8 million, up 41%, indicating strong market performance and rising customer demand.
- Record Gross Margin: The company achieved a nearly 80% non-GAAP gross margin, up from 75.3% last year, reflecting improved cost control and operational efficiency, which lays a solid foundation for future profitability.
- Strong Customer Growth: HeartFlow added 340 new accounts in 2025, marking the strongest new account growth in the company's history, demonstrating increasing acceptance and competitiveness of its products in the market.
- Optimistic Outlook: The company projects 2026 revenue guidance between $218 million and $222 million, representing a growth of 24% to 26%, with plaque revenue expected to reach $15 million to $17 million, showcasing confidence in future market opportunities.
See More
HeartFlow Reports Strong Q4 2025 Earnings with Robust Growth Outlook
- Outstanding Financial Performance: HeartFlow reported Q4 2025 revenue of $49.1 million, reflecting over 40% year-over-year growth, with global case volume increasing nearly 53% and non-GAAP gross margin approaching 80%, indicating strong market demand and execution in the cardiac health sector.
- 2026 Revenue Guidance: The company projects total revenue for 2026 to be between $218 million and $222 million, representing an expected year-over-year growth of approximately 24% to 26%, with plaque revenue anticipated to contribute $15 million to $17 million, showcasing confidence in clinical experience and market expansion.
- Innovative Product Launch: HeartFlow is set to launch PCI Navigator, an AI-driven planning tool for interventional cardiologists, ahead of schedule in April 2026, marking significant progress in technology innovation and responsiveness to market needs.
- Market Expansion Strategy: The company plans to initiate three randomized controlled trials in the high-risk asymptomatic population over the next 12 months, estimating this market at $6 billion, further solidifying its position in the cardiac health sector.
See More
HeartFlow Reports Q4 Earnings Beat with Strong Guidance
- Earnings Beat: HeartFlow reported a Q4 non-GAAP EPS of -$0.12, surpassing expectations by $0.04, indicating a positive trend in profitability recovery that may boost investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $49.1 million, a 40.3% year-over-year increase, exceeding market expectations by $2.6 million, demonstrating strong product demand and expanding market share.
- Optimistic Future Guidance: HeartFlow projects total revenue for 2026 to be between $218 million and $222 million, reflecting a year-over-year growth rate of approximately 24% to 26%, significantly above the consensus estimate of $173.41 million, showcasing confidence in future growth.
- Stable Gross Margin: The company anticipates a non-GAAP gross margin of 80% to 81%, indicating ongoing improvements in cost control and profitability, which may enhance investor confidence in its long-term financial health.
See More
Heartflow Reports 40% Revenue Growth in 2025 Financial Results
- Significant Revenue Growth: Heartflow reported total revenue of $49.1 million for Q4 2025, marking a 40% year-over-year increase, with U.S. revenue at $44.8 million, up 41%, indicating strong market demand for its AI technology in coronary artery disease.
- Margin Improvement: The gross margin for Q4 was 79.5%, up from 75.0% in the prior year, with a non-GAAP gross margin of 79.9%, primarily driven by increased revenue case volume and enhanced production team productivity, reflecting successful cost control and operational efficiency.
- Narrowing Net Loss: The net loss for Q4 2025 was $24.4 million, an improvement from $32.9 million in the same quarter last year, with a non-GAAP net loss of $9.8 million, showcasing gradual financial performance improvement and enhanced operational efficiency.
- Optimistic 2026 Outlook: Heartflow anticipates total revenue for 2026 to be between $218 million and $222 million, representing a year-over-year growth of approximately 24% to 26%, with non-GAAP gross margins expected to reach 80% to 81%, indicating strong confidence in future growth and market potential.
See More
Capricorn Investment Group Acquires HeartFlow Shares Worth $48.18 Million
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025, with an estimated transaction value of $48.18 million, indicating confidence in the company's future prospects.
- Asset Impact: This acquisition accounts for 5.83% of Capricorn's 13F reportable assets, although HeartFlow does not rank among the fund's top five holdings, reflecting a selective investment strategy.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, marking a robust 40% year-over-year increase, yet it reported a net loss of $24.4 million, highlighting ongoing efforts to manage costs effectively.
- Market Risks: Despite HeartFlow's price-to-sales ratio nearing a low since its IPO, investors should proceed with caution as the company remains unprofitable and its stock price has declined by 10.7% in 2026.
See More
Capricorn Investment Group Acquires HeartFlow Shares
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025 for approximately $48.18 million, reflecting confidence in the company's future prospects.
- Asset Allocation: The new HeartFlow position represents 5.83% of Capricorn's reportable assets under management, highlighting its significance in a portfolio that includes only seven holdings.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, a robust 40% year-over-year increase, yet reported a net loss of $24.4 million, indicating ongoing efforts to manage costs effectively.
- Market Opportunity: With a price-to-sales ratio of 12 near its IPO low, HeartFlow's declining share price suggests a potential buying opportunity for investors looking to capitalize on future growth despite the inherent risks of a newly public company.
See More
HeartFlow Reports 40% Revenue Growth in Q4 2025
- Significant Revenue Growth: HeartFlow reported total revenue of $49.1 million for Q4 2025, marking a 40% year-over-year increase, with US revenue reaching $44.8 million, up 41%, indicating strong market performance and rising customer demand.
- Record Gross Margin: The company achieved a nearly 80% non-GAAP gross margin, up from 75.3% last year, reflecting improved cost control and operational efficiency, which lays a solid foundation for future profitability.
- Strong Customer Growth: HeartFlow added 340 new accounts in 2025, marking the strongest new account growth in the company's history, demonstrating increasing acceptance and competitiveness of its products in the market.
- Optimistic Outlook: The company projects 2026 revenue guidance between $218 million and $222 million, representing a growth of 24% to 26%, with plaque revenue expected to reach $15 million to $17 million, showcasing confidence in future market opportunities.
See More
HeartFlow Reports Strong Q4 2025 Earnings with Robust Growth Outlook
- Outstanding Financial Performance: HeartFlow reported Q4 2025 revenue of $49.1 million, reflecting over 40% year-over-year growth, with global case volume increasing nearly 53% and non-GAAP gross margin approaching 80%, indicating strong market demand and execution in the cardiac health sector.
- 2026 Revenue Guidance: The company projects total revenue for 2026 to be between $218 million and $222 million, representing an expected year-over-year growth of approximately 24% to 26%, with plaque revenue anticipated to contribute $15 million to $17 million, showcasing confidence in clinical experience and market expansion.
- Innovative Product Launch: HeartFlow is set to launch PCI Navigator, an AI-driven planning tool for interventional cardiologists, ahead of schedule in April 2026, marking significant progress in technology innovation and responsiveness to market needs.
- Market Expansion Strategy: The company plans to initiate three randomized controlled trials in the high-risk asymptomatic population over the next 12 months, estimating this market at $6 billion, further solidifying its position in the cardiac health sector.
See More
HeartFlow Reports Q4 Earnings Beat with Strong Guidance
- Earnings Beat: HeartFlow reported a Q4 non-GAAP EPS of -$0.12, surpassing expectations by $0.04, indicating a positive trend in profitability recovery that may boost investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $49.1 million, a 40.3% year-over-year increase, exceeding market expectations by $2.6 million, demonstrating strong product demand and expanding market share.
- Optimistic Future Guidance: HeartFlow projects total revenue for 2026 to be between $218 million and $222 million, reflecting a year-over-year growth rate of approximately 24% to 26%, significantly above the consensus estimate of $173.41 million, showcasing confidence in future growth.
- Stable Gross Margin: The company anticipates a non-GAAP gross margin of 80% to 81%, indicating ongoing improvements in cost control and profitability, which may enhance investor confidence in its long-term financial health.
See More
Heartflow Reports 40% Revenue Growth in 2025 Financial Results
- Significant Revenue Growth: Heartflow reported total revenue of $49.1 million for Q4 2025, marking a 40% year-over-year increase, with U.S. revenue at $44.8 million, up 41%, indicating strong market demand for its AI technology in coronary artery disease.
- Margin Improvement: The gross margin for Q4 was 79.5%, up from 75.0% in the prior year, with a non-GAAP gross margin of 79.9%, primarily driven by increased revenue case volume and enhanced production team productivity, reflecting successful cost control and operational efficiency.
- Narrowing Net Loss: The net loss for Q4 2025 was $24.4 million, an improvement from $32.9 million in the same quarter last year, with a non-GAAP net loss of $9.8 million, showcasing gradual financial performance improvement and enhanced operational efficiency.
- Optimistic 2026 Outlook: Heartflow anticipates total revenue for 2026 to be between $218 million and $222 million, representing a year-over-year growth of approximately 24% to 26%, with non-GAAP gross margins expected to reach 80% to 81%, indicating strong confidence in future growth and market potential.
See More
